The much-anticipated Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion imaging agent for the detection of coronary artery disease, ...
GE HealthCare’s FDA-approved flurpiridaz F 18 PET radiotracer, Flyrcado, delivers higher diagnostic efficacy in patients with known or suspected coronary artery disease (CAD), compared to SPECT MPI, ...
A new approach to PET imaging offers a promising way for physicians to promptly identify patients who are at risk for poor functional recovery after a heart attack, according to new research published ...
A novel tracer for positron emission tomography (PET) myocardial perfusion imaging, called flurpiridaz F-18, performed well in a second phase III trial when it came to the detection of CAD in patients ...
The emerging advantages of positron-emission tomography (PET) myocardial perfusion imaging (MPI) for coronary artery disease (CAD) diagnosis and assessment of cardiovascular event risk has prompted ...
First Pediatric Hospital in the United States to Feature Low-Field MRI Technology Children’s Hospital Los Angeles has opened its new Cardiac Imaging Suite, a 6,650-square-foot facility that will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback